Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul 3:5:63-72.
doi: 10.2147/DNND.S37268. eCollection 2015.

Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations

Tigran Kesayan  1 , Jessica D Shaw  1 , Tracy M Jones  1 , Joseph S Staffetti  1 , Theresa A Zesiewicz  1   2
Affiliations
Review

Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations

Tigran Kesayan et al. Degener Neurol Neuromuscul Dis. .

Erratum in

Abstract

Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson's disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson's disease and RLS.

Keywords: Parkinson’s disease; dopamine agonist; restless legs syndrome; rotigotine.

PubMed Disclaimer

Conflict of interest statement

T Kesayan, JD Shaw, T Jones, and JS Staffetti have nothing to disclose and have no conflict of interest in this work. TA Zesiewicz receives grant funding from Edison Pharmaceuticals, Inc., Sagene Pharmaceuticals, Inc., the Friedreich’s Ataxia Research Alliance, Osmotica Pharmaceutical Corp, Adamas Pharmaceuticals, Inc., and Baxter Pharmaceuticals, Inc. She has no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Structural formula of rotigotine. Note: *Chiral center.
See this image and copyright information in PMC

References

    1. Elshoff J-P, Cawello W, Andreas J-O, Mathy F-X, Braun M. An update on pharmacological, pharmacokinetic properties and drug–drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75(5):487–501. - PMC - PubMed
    1. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404. - PubMed
    1. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2009;10(4): 677–691. - PubMed
    1. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73–86. - PubMed
    1. NEUPRO Prescribing Information. ©2015 UCB, Inc., Smyrna, GA 30080 All rights Reserv; 2015.